This page shows the latest PD-L1/ PD-1 inhibitor news and features for those working in and with pharma, biotech and healthcare.
RCC that has progressed following PD-1/L1 checkpoint inhibitor and vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) therapies. ... Patients with advanced RCC face low survival rates, and for those whose cancer progresses following
Interim results from the phase 3 AEGEAN study, which is assessing the PD-1/L1 inhibitor in combination with neoadjuvant chemotherapy before surgery and as a monotherapy after surgery, showed the
Interim results from the AEGEAN study, which is assessing the PD-1/L1 inhibitor in combination with neoadjuvant chemotherapy before surgery and as a monotherapy after surgery, showed the regimen reduced ... Imfinzi is a human monoclonal antibody that
In cohort one, which assessed mUC patients whose cancer had progressed after platinum-based chemotherapy and checkpoint inhibitor therapy (CPI), Trodelvy was associated with a 10.9 months median overall survival, ... The drug has already received
L1 inhibitor (PD-1/PD-L1-naïve) and one of patients who had received prior PD-1 or PD-L1 inhibitor therapy (PD-1/PD-L1-experienced). ... The objective response rate (ORR) in the PD-1/PD-L1-experienced cohort was 13%.
Bintrafusp alfa is part of a new wave of bispecific antibodies that are currently being developed by a number of companies as potential successors to the PD-1/PD-L1 inhibitor ... class. The molecule is designed to simultaneously target two
More from news
Approximately 1 fully matching, plus 64 partially matching documents found.
cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
Avalere Health is a leading global commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Working from advisory to...